Latest Decheng Capital LLC Stock Portfolio
Decheng Capital LLC Performance:
2025 Q3: 47.91%YTD: 23.95%2024: -8.09%
Performance for 2025 Q3 is 47.91%, and YTD is 23.95%, and 2024 is -8.09%.
About Decheng Capital LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, Decheng Capital LLC reported an equity portfolio of $573.2 Millions as of 30 Sep, 2025.
The top stock holdings of Decheng Capital LLC are , NUVB, . The fund has invested 44.8% of it's portfolio in CG ONCOLOGY INC and 16.8% of portfolio in NUVATION BIO INC.
The fund managers got completely rid off ARCELLX INC (ACLX) and LEGEND BIOTECH CORP-ADR stocks. They significantly reduced their stock positions in 4D MOLECULAR THERAPEUTICS IN (FDMT), KRYSTAL BIOTECH INC (KRYS) and NEWAMSTERDAM PHARMA CO NV (NAMS). The fund showed a lot of confidence in some stocks as they added substantially to ARCUS BIOSCIENCES, INC (RCUS).
The top stock holdings of Decheng Capital LLC are , NUVB, . The fund has invested 44.8% of it's portfolio in CG ONCOLOGY INC and 16.8% of portfolio in NUVATION BIO INC.
The fund managers got completely rid off ARCELLX INC (ACLX) and LEGEND BIOTECH CORP-ADR stocks. They significantly reduced their stock positions in 4D MOLECULAR THERAPEUTICS IN (FDMT), KRYSTAL BIOTECH INC (KRYS) and NEWAMSTERDAM PHARMA CO NV (NAMS). The fund showed a lot of confidence in some stocks as they added substantially to ARCUS BIOSCIENCES, INC (RCUS).
Decheng Capital LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Decheng Capital LLC made a return of 47.91% in the last quarter. In trailing 12 months, it's portfolio return was 9.73%.
New Buys
Additions
| Ticker | % Inc. |
|---|---|
| arcus biosciences, inc | 242 |
Additions to existing portfolio by Decheng Capital LLC
Reductions
| Ticker | % Reduced |
|---|---|
| 4d molecular therapeutics in | -61.28 |
| krystal biotech inc | -51.06 |
| newamsterdam pharma co nv | -14.67 |
| revolution medicines inc(nsm) | -7.08 |
| beyondspring inc. | -5.41 |
| merus nv | -1.35 |
Decheng Capital LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| arcellx inc | -4,457,540 |
| legend biotech corp-adr | -709,800 |
Decheng Capital LLC got rid off the above stocks
Sector Distribution
Decheng Capital LLC has about 66.3% of it's holdings in Others sector.
| Sector | % |
|---|---|
| Others | 66.3 |
| Healthcare | 33.7 |
Market Cap. Distribution
Decheng Capital LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| UNALLOCATED | 69.6 |
| SMALL-CAP | 20.5 |
| MID-CAP | 6.8 |
| MICRO-CAP | 1.9 |
| NANO-CAP | 1.1 |
Stocks belong to which Index?
About 25.9% of the stocks held by Decheng Capital LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 74 |
| RUSSELL 2000 | 25.9 |
Decheng Capital LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Decheng Capital LLC
Decheng Capital LLC has 23 stocks in it's portfolio. About 93.8% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. was the most profitable stock for Decheng Capital LLC last quarter.
Last Reported on: 14 Nov, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ACRS | aclaris therapeutics, inc. | 1.34 | 4,041,740 | 7,679,300 | unchanged | 0.00 | ||
| AURA | aura biosciences, inc. | 0.56 | 515,555 | 3,186,130 | unchanged | 0.00 | ||
| BYSI | beyondspring inc. | 1.35 | 4,286,100 | 7,757,850 | reduced | -5.41 | ||
| CRNX | crinetics pharmaceuticals in | 1.04 | 143,000 | 5,955,950 | unchanged | 0.00 | ||
| EQ | equillium inc. | 1.11 | 4,447,310 | 6,359,650 | unchanged | 0.00 | ||
| FDMT | 4d molecular therapeutics in | 0.14 | 92,748 | 805,980 | reduced | -61.28 | ||
| ILMN | illumnia, inc. | 0.13 | 7,979 | 757,766 | unchanged | 0.00 | ||
| KRYS | krystal biotech inc | 1.00 | 32,300 | 5,701,920 | reduced | -51.06 | ||
| LYEL | lyell immunopharma, inc. | 1.69 | 595,466 | 9,670,370 | unchanged | 0.00 | ||
| MRUS | merus nv | 3.06 | 186,546 | 17,563,300 | reduced | -1.35 | ||
| NAMS | newamsterdam pharma co nv | 3.26 | 657,051 | 18,686,500 | reduced | -14.67 | ||
| NUVB | nuvation bio inc. | 16.75 | 25,954,400 | 96,031,400 | unchanged | 0.00 | ||
| NUVB | nuvation bio inc. | 0.02 | 646,057 | 115,458 | unchanged | 0.00 | ||
| PYXS | pyxis oncology, inc (formerly apexigen) | 0.13 | 326,810 | 725,518 | unchanged | 0.00 | ||
| RCUS | arcus biosciences, inc | 1.30 | 547,609 | 7,447,480 | added | 242 | ||
| RVMD | revolution medicines inc(nsm) | 1.71 | 210,000 | 9,807,000 | reduced | -7.08 | ||
| RZLT | rezolute inc | 0.10 | 59,900 | 563,060 | unchanged | 0.00 | ||
| ZNTL | zentalis pharmaceuticals inc. | 0.35 | 1,323,330 | 1,998,220 | unchanged | 0.00 | ||
| cg oncology inc | 44.77 | 6,371,670 | 256,651,000 | unchanged | 0.00 | |||